Managed Healthcare Executive23h
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
LGBTQ Nation on MSN18h
Once-a-year shot for HIV protection passes early safety trial
An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
This New Drug Could Help End the HIV Epidemic—but US Funding Cuts Are Killing Its Rollout
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Queerty on MSN1d
A once-a-year PrEP injection? The results of the first clinical trial look promising
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Annual jab for HIV protection passes trial hurdle
An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...
BBC3d
Annual jab for HIV protection passes trial hurdle
Currently, people can take daily pills or sometimes have injections every eight weeks, for pre-exposure prophylaxis (PrEP), to reduce their risk. PrEP tablets are highly effective but taking them ...